🔗 Share this article

While America continues making historic changes to its vaccine recommendations, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by questioning Covid vaccinations throughout the pandemic and has concentrated on possible deaths after Covid vaccination in her short tenure at the FDA.

Proposed Changes to Pediatric Vaccine Program

Public health authorities planned to announce major revisions to the childhood vaccine schedule earlier this month, synchronizing the US with Denmark’s national calendar, it is understood – a substantial departure that would place the US out of step with many the international standard with no evidence for public health gain. The announcement has been postponed until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to speak at the meeting. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this year.

A Shift at the Regulatory Body

This interim role may indicate a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a increased emphasis upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has often pushed for halting some childhood shot schedules in the US in order to be more in line with Denmark's approach, a country with universal health coverage and a population about the population of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccination policy – usually the responsibility of Dr. Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Qualifications

The appointee has no apparent experience in pharmaceutical research, approval processes or leadership, which has been customary for previous leaders of the CBER. She has served at the FDA as a senior adviser to the agency head and the vaccine center since March.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, said Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in leading a major agency. She has no expertise in drug approvals.”

Previous commissioners of the center would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that former directors who led CBER have had.”

The drug center has an enormous workload at the FDA, Woodcock pointed out.

“Everybody just focuses on the innovative therapies, but the generic drug division approves numerous off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and more, and all of those need to be managed,” Dr. Woodcock explained. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Furthermore, a significant management component to the role, which oversees over 5,000 staff members. “It is a massive administrative position, if you perform it correctly,” she concluded.

Agency Reaction and Disputed Programs

Regarding concerns about Høeg’s qualifications and whether this assignment signifies increased cooperation among regulatory chiefs on vaccines, a representative responded that the “inquiries rely on inaccurate premises”.

“Her experience aligns with the responsibilities of her role,” the official said, noting the period Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched expedited review system, a controversial expedited drug-approval program that allegedly concerned her preceding directors. “How are these drugs being selected for this voucher program? Who makes the decisions?” Howard questioned. “There’s a lot of confidentiality occurring at the FDA right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards laxer regulations of all drugs, aside from immunizations.”

Public History on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if troubling, past, critics have noted. She released a analysis using unconfirmed public submissions to determine the rate of myocarditis after Covid vaccination. She advised the state of Florida top health official Joseph Ladapo, who reportedly have altered data to indicate Covid vaccines are riskier than they are.

Included in her “desired changes” for the current federal leadership encompassed altering rules for recently developed shots and ending “non-essential” immunizations, she stated post-election on a podcast. At the agency, Høeg has reportedly suggested barring teenage boys from getting Covid vaccinations.

“She’s an thorough true believer who starts off with her conclusions and works backwards to retrofit the evidence in a very disingenuous, fraudulent manner,” Howard stated.

Gaining Influence and a “Push for Payback”

Høeg joined other dissenters, {like|